A Phase II Study of Triple-negative Breast Cancer Brain Metastases.
NCT04303988 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35
Last updated 2024-07-18
Summary
Study to assess the effectiveness and safety of SHR 1316, bevacizumab combined with cisplatin/carboplatin for treatment of triple-negative breast cancer brain metastases.
Conditions
Interventions
- DRUG
-
SHR-1316
IV
- DRUG
-
IV
- DRUG
-
Cisplatin/Carboplatin
IV
Sponsors & Collaborators
-
Fudan University
lead OTHER
Principal Investigators
-
Jian Zhang, MD · Fudan University
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-03-30
- Primary Completion
- 2024-12-30
- Completion
- 2025-05-30
Countries
- China
Study Locations
More Related Trials
-
Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment
NCT05132790 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases
NCT06361979 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China
NCT04334330 ·Status: UNKNOWN ·Phase: PHASE2
-
Reverse Triple Negative Immune Resistant Breast Cancer
NCT05076682 ·Status: RECRUITING ·Phase: PHASE2
-
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
NCT04437160 ·Status: RECRUITING ·Phase: PHASE2
-
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
NCT05806060 ·Status: RECRUITING ·Phase: PHASE3
-
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
NCT05769010 ·Status: RECRUITING ·Phase: PHASE2
-
A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases
NCT07177950 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy
NCT05303038 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.
NCT04335006 ·Status: TERMINATED ·Phase: PHASE3
-
Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients
NCT01658033 ·Status: COMPLETED ·Phase: PHASE2
-
An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.
NCT04395989 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer
NCT01276769 ·Status: UNKNOWN ·Phase: PHASE2
-
A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
NCT05862064 ·Status: RECRUITING ·Phase: PHASE3
-
Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)
NCT04031703 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer
NCT05681728 ·Status: UNKNOWN ·Phase: PHASE2
-
ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases
NCT05018702 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
NCT04907344 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
NCT05909332 ·Status: RECRUITING ·Phase: PHASE3
-
Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer
NCT03907800 ·Status: UNKNOWN ·Phase: PHASE2
-
Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients
NCT05174832 ·Status: UNKNOWN ·Phase: PHASE2
-
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
NCT06404736 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
NCT03644589 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Phase II Study of SHR-A1811 Combined With Radiotherapy in HER2-positive and HER2-low Breast Cancer Brain Metastases
NCT06975462 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer
NCT01238952 ·Status: COMPLETED ·Phase: PHASE1